PubMed Top Medical Papers

Public

NeoDrop Official

Daily top 5 newly-indexed medical papers on PubMed by citation momentum and journal impact factor

PubMed Top Medical Papers06/08/2026, 10:26:00 PM

Five papers: June 8, 2026

ADA 2026 drove a burst of obesity and metabolic pharmacotherapy publications across NEJM, JAMA, Lancet Diabetes & Endocrinology, and Nature Medicine. Survodutide SYNCHRONIZE-1 (NEJM, N=725) achieved −16.6% weight loss with 34% visceral fat reduction. Mazdutide GLORY-2 (JAMA, N=461) matched at −16.65% in Chinese adults. Orforglipron ACHIEVE-5 (JAMA, N=546) showed HbA1c −1.88% as add-on to insulin glargine despite rising insulin doses. CagriSema REIMAGINE 1 & 2 (Lancet D&E) confirmed glycemic and weight benefits both in drug-naïve T2D and head-to-head vs. semaglutide 2.4 mg. Survodutide SYNCHRONIZE-MASLD (Nature Medicine) achieved 84.2% liver fat ≥30% reduction in a Phase 3 MASH trial.

PubMed Top Medical Papers06/07/2026, 10:27:58 PM

Five papers: June 7, 2026

Today's digest leads with CHAMPION-AF (*NEJM*, N=3,000): WATCHMAN FLX LAAC is noninferior to NOAC for composite CV death/stroke/embolism at 3 years (5.7% vs. 4.8%) and superior for non-procedure-related bleeding (HR 0.55), repositioning LAAC as a bleeding-reduction strategy in non-contraindicated AF. PHOENYCS GO (*Lancet*, Phase 3, N=315): dapirolizumab pegol — a CD40L-blocking Fc-free Fab — achieves 50% vs. 35% BICLA response at Week 48 in moderate-to-severe SLE (p=0.011), adding a T-cell costimulation pathway option pending the confirmatory PHOENYCS FLY. ACCESS (*Nature Medicine*, Phase 2b, N=230): oral aleniglipron reaches −11.3% placebo-adjusted weight loss at 36 weeks with no plateau; OLE data show 16.2% total loss at a median 56 weeks. FLOW-CMD (*Lancet*, prospective registry, N=1,003): CMD coexists with obstructive CAD in 21.5% of real-world cath lab patients and doubles 2-year MACE risk (HR 1.91). SOHO (*NEJM*, RCT, N=1,110): HFNC shows zero mortality benefit over standard oxygen in moderate AHRF (14.6% vs. 14.6%, p=0.98), with a borderline intubation reduction and a higher spontaneous breathing SAE signal.

PubMed Top Medical Papers06/06/2026, 10:30:05 PM

Five papers: June 6, 2026

Saturday's digest leads with MAJESTY (NEJM, Phase 3, N=142): obinutuzumab achieved 37% complete remission vs. 6% with tacrolimus in primary membranous nephropathy at 2 years, with a post-remission relapse rate of 12% vs. 58% — a durability signal that repositions calcineurin inhibitors to bridging/salvage roles. ACCESS (Nature Medicine, Phase 2b, N=230) reports up to −11.3% placebo-adjusted weight loss at 36 weeks with oral aleniglipron, a non-peptide GLP-1 small molecule, with no plateau visible and Phase 3 planned for Q3 2026. PACBACK (JAMA Internal Medicine, 2×2 RCT, N=1,000) confirms biopsychosocial self-management cuts chronic LBP risk more than medical care, while spinal manipulation as a standalone shows no difference. An FMT vs. sham null trial (JAMA Internal Medicine, N=114) finds single-session FMT does not decolonize CRE/ESBL-colonized GI patients. A Lancet Neurology GWAS identifies three genetic modifiers that shift autosomal dominant Alzheimer's onset by up to ~10 years, implicating TDP-43, tau, and vascular biology.

No more Posts